aricept

Anyone who hasn’t realized that the Alzheimer’s Association is a drug industry shill, there to push worthless drugs like Aricept, just isn’t cynical enough for today’s world! They hate nutritional therapy. In Sri Lanka, I was blocked from addressing an AA meeting, once they knew I was to talk about vital nutrition. Now patients are warned about a daily drink combining several nutrients which may help people with early Alzheimer’s disease improve their memory, according to a new study. Of course the Alzheimer’s Association attacked it. “More research is needed before such a deadly drink could be made available to the public. And, even then, consumers should exercise caution,” said William Thies, vice president for medical and scientific affairs at the Alzheimer’s Association! As Alzheimer’s progresses, patients lose their memory as synapses (connections between brain cells) deteriorate, according to background information included in the study. The new drink, called Souvenaid, may actually stimulate the growth of new synapses, said the drink’s inventor, Massachusetts Institute of Technology scientist Dr. Richard Wurtman. Nutricia, a division of Dannon, the food people, sponsored the study. MIT has a patent on Souvenaid, and Nutricia has the exclusive license on the patent. So of course they are excited about it. Imagine getting a patent on Nature’s healthy molecules!

Anyone who hasn’t realized that the Alzheimer’s Association is a drug industry shill, there to push worthless drugs like Aricept, just isn’t cynical enough for today’s world! They hate nutritional therapy. In Sri Lanka, I was blocked from addressing an AA meeting, once they knew I was to talk about vital nutrition. Now patients are warned about a daily drink combining several nutrients which may help people with early Alzheimer’s disease improve their memory, according to a new study. Of course the Alzheimer’s Association attacked it. “More research is needed before such a deadly drink could be made available to the public. And, even then, consumers should exercise caution,” said William Thies, vice president for medical and scientific affairs at the Alzheimer’s Association! As Alzheimer’s progresses, patients lose their memory as synapses (connections between brain cells) deteriorate, according to background information included in the study. The new drink, called Souvenaid, may actually stimulate the growth of new synapses, said the drink’s inventor, Massachusetts Institute of Technology scientist Dr. Richard Wurtman. Nutricia, a division of Dannon, the food people, sponsored the study. MIT has a patent on Souvenaid, and Nutricia has the exclusive license on the patent. So of course they are excited about it. Imagine getting a patent on Nature’s healthy molecules!

The current medical thinking is that Alzheimer’s disease (AD) is a deficit in neurotransmitter function; specifically acetylcholine. Doctors have become obsessed with the characteristic amyloid plaques which are found in Alzheimer’s brains. But there is no evidence whatever that these plaques are the cause of Alzheimer’s. In fact scientific studies say the opposite. Drugs designed to reduce the presence of plaques have no significant effect on the progression of AD. Moreover drugs designed to rectify the acetylcholine deficiency also fail miserably, even though they are pushed with phoney science and TV advertizing hype (Aricept etc. are worthless). All this is despite the fact that there is a better model for AD. It’s better because rectifying it results in dramatic improvement. Alzheimer’s patients suffer from a metabolic disruption that inhibits the brain’s ability to use glucose to power neurons.

The current medical thinking is that Alzheimer’s disease (AD) is a deficit in neurotransmitter function; specifically acetylcholine. Doctors have become obsessed with the characteristic amyloid plaques which are found in Alzheimer’s brains. But there is no evidence whatever that these plaques are the cause of Alzheimer’s. In fact scientific studies say the opposite. Drugs designed to reduce the presence of plaques have no significant effect on the progression of AD. Moreover drugs designed to rectify the acetylcholine deficiency also fail miserably, even though they are pushed with phoney science and TV advertizing hype (Aricept etc. are worthless). All this is despite the fact that there is a better model for AD. It’s better because rectifying it results in dramatic improvement. Alzheimer’s patients suffer from a metabolic disruption that inhibits the brain’s ability to use glucose to power neurons.